SRI and faith-based investors warn of continued failure to fully appreciate risks to industry from pediatric HIV and generalized HIV-TB-Malaria pandemics
Boston, MA – The Benchmarking AIDS report released by ICCR earlier this year finds that pharmaceutical companies’ response is still lacking in key areas including access to treatment for children and child-to-mother prevention.
